What the STEP trial found about semaglutide withdrawal and weight regain

You've stopped semaglutide. Here's what the trial data says happens next

Imagine you completed 68 weeks of semaglutide 2.4mg treatment, lost around 15% of your starting weight, and then stopped. That's the scenario the STEP 1 withdrawal extension was designed to study, and what researchers found was striking. Over the following 12 months, participants regained on average about two-thirds of the weight they had lost. By week 120 (roughly a year after stopping), body weight had returned to within a few percentage points of baseline for many people.

It's worth being precise about what that means in practice. Someone who lost 15 kg during treatment might expect to regain 9–10 kg within the year after stopping, though individual variation is wide. The regain wasn't an immediate cliff-edge: it was gradual in the first few months, then picked up pace as semaglutide cleared the body and appetite regulation returned to its pre-treatment state. The STEP 1 extension data is the most detailed picture we have of this pattern, and it's the evidence base cited in clinical guidance.

Crucially, the metabolic gains made during treatment (lower blood pressure, improved fasting glucose, reduced waist circumference) also partially unwound. They didn't vanish overnight, but they tracked the weight trajectory closely. That has real implications for people managing obesity alongside conditions like hypertension or prediabetes.

Why regain happens: the biology, not the willpower

A question our prescribers hear most weeks is some version of: "Does regaining weight after stopping mean the treatment didn't work?" The honest answer is no. Semaglutide works by activating GLP-1 receptors involved in appetite regulation and the sense of fullness after eating. While the medicine is present, those signals are amplified. When it's gone, the body's weight-regulating hormones (ghrelin, leptin, and others) return to their pre-treatment levels.

The STEP trial findings are consistent with what we understand about obesity as a long-term condition. Body weight has a regulated set-point that biology actively defends; after significant weight loss, the body tends to push back. Semaglutide's weight-loss results during treatment are real and clinically meaningful, but they depend on the medicine being present to maintain the effect. Stopping treatment is not like completing a course of antibiotics where the job is done; it's more like stopping a blood pressure tablet and expecting the pressure to stay controlled.

Understanding this reframes stopping as a clinical decision rather than a personal one. It also means that planning what happens after a course of treatment is just as important as the treatment itself, something worth discussing with your prescriber well in advance of stopping. You can read more about the experience of how semaglutide works over time and what the timeline looks like from the first dose.

What can slow or reduce the regain?

The STEP 1 withdrawal data doesn't mean regain is inevitable at that scale for everyone. Several factors appear to moderate the trajectory, and some of them are within reach. The clearest evidence points to sustained behavioural change (diet quality, protein adequacy, and regular resistance activity) as buffers against rapid regain, even if they can't fully counteract the hormonal drivers. The NHS's own guidance on semaglutide recommends continuing with a reduced-calorie diet and increased physical activity as part of any treatment plan, and that remains relevant after stopping.

For people who don't want to stop, or who have stopped and are watching weight return, the clinical conversation is increasingly about long-term or indefinite treatment, a position supported by NICE's appraisal of semaglutide and the broader obesity-medicine literature. The STEP 1 trial paper in the New England Journal of Medicine includes the maintenance-phase data and is the primary source for these figures. There is also a separate page exploring practical strategies for minimising regain after Wegovy that goes into more detail on lifestyle and clinical options.

It's also worth knowing that when regain starts after stopping semaglutide varies, some people see early shifts within weeks; others hold their weight for longer before it creeps back. Individual factors including starting weight, how much was lost, and metabolic health all play a role. None of it is quick to read as a verdict.

Thinking about what comes next

If you're weighing up whether to continue, restart or move to a different treatment, that conversation belongs with a prescriber who knows your medical history. Semaglutide (Wegovy) is a prescription-only medicine; continuing it, stopping it, or switching requires clinical assessment each time. Private treatment through a regulated pharmacy gives you access to that assessment without a waiting list. For context on how pricing fits into the longer-term picture, the Wegovy price comparison page walks through what typical costs look like across providers.

At nume, every repeat order is reviewed by a GPhC-registered prescriber before dispatch, so if you're returning after a gap, or thinking about restarting, there's a clinical check built into the process. Check your eligibility and start a free consultation whenever you're ready to talk it through.